|
Video: What is a Stock Split?
|
|
Horizon Therapeutics is focused on researching, developing and commercializing medicines that address the needs for people with rare and rheumatic diseases. Co. has two segments, the orphan segment and the inflammation segment. The Orphan segment includes: TEPEZZA, which is indicated for the treatment of thyroid eye diseas; KRYSTEXXA, which is indicated for the treatment of uncontrolled gout; and PROCYSBI, which is indicated for nephropathic cystinosis. The Inflammation segment includes: PENNSAID 2% w/w, which is indicated for the treatment of pain of osteoarthritis (OA), of the knee(s); and DUEXIS, which is indicated for the relief of signs and symptoms of rheumatoid arthritis and OA. According to our HZNP split history records, Horizon Therapeutics Public Limited - Ordi has had 0 splits. | |
|
Horizon Therapeutics Public Limited - Ordi (HZNP) has 0 splits in our HZNP split history database.
Looking at the HZNP split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Horizon Therapeutics Public Limited - Ordi shares, starting with a $10,000 purchase of HZNP, presented on a split-history-adjusted basis factoring in the complete HZNP split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
03/31/2014 |
|
End date: |
10/06/2023 |
|
Start price/share: |
$15.12 |
|
End price/share: |
$116.30 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
669.18% |
|
Average Annual Total Return: |
23.89% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$76,914.99 |
|
Years: |
9.52 |
|
|
|
|
|